Entries by Ayal Ronen

Presentation: 2014 Non-dilutive Funding Forecast

The 9th Annual Non-dilutive Funding Summit is proud to host Ram May-Ron, Managing Partner,  FreeMind Group who will give a presentation on a “2014 Non-Dilutive Funding Forecast”. In his presentation Mr May-Ron will share his insight into Life Science funding trends and specifically non-dilutive funding as the driving force in this sector.

Direct Phase II SBIR Grants to Support Biomedical Technology Development

The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism.  Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, […]

Partnerships in Clinical Trials

Meet FreeMind at the Partnership in Clinical trials event in Las Vegas on March 30th to discuss sources of funding able to fund your clinical trial! For more than 22 years, Partnerships has been a cornerstone for thousands of clinical executives to partner, learn, and innovate. This coming year, we’re taking PCT to a whole […]

$580,000,000 CDMRP Awards Appropriated for 2014!

The Fiscal Year 2014 Department of Defense Appropriations Act will fund some$580,000,000 through the Congressionally Directed Medical Research Programs (CDMRP). Programs range from Oncology, ALS, Autism, through MS, Orthopedic research and more. Program Announcements will be issued during 2014, Stay Tuned!  The FreeMind Group has extensive experience in assisting clients in completing and winning such complex […]

9th Annual Non-dilutive Funding Summit

[vc_row][vc_column width=”1/1″][pt_heading h=”h3″ heading=” Join over 250 life science industry leaders in a full day of non-dilutive funding activities at the 9th Annual Non-dilutive Funding Summit, taking place on Wednesday January 15th, 2014 at the Nikko Hotel San Francisco. ” text_align=”align-left”][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][vc_separator][/vc_column][/vc_row][vc_row][vc_column width=”1/1″][pt_text text_align=”align-left”] The summit is proud to host Dr Jodi Black of the […]

CEOCFO Magazine Interviews Ram May-Ron, FreeMind’s Managing Partner – Securing Non-Dilutive Source Funding for Life Science Industry Companies

Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – October 14, 2013 [PDF Article] CEOCFO: Mr. May-Ron, what is the vision and concept at FreeMind Group? Mr. May-Ron: What we are trying to do is just one thing. Within the life science industry there are three main sources of funding globally as well as the […]

Harvard i-lab | Presentation by Ram May-Ron, Managing Partner FreeMind; Non-Dilutive Funding for Early-Stage Life Sciences Companies and Beyond

Presentation at the Harvard Innovation Lab by Ram May-Ron, Managing Partner FreeMind. Synopsis: Explore ways to maximize funding for science companies from non-dilutive funding sources such as NIH, DOD SBIRs (Small Business Innovation Research) and other federal and private sources. Learn about successful strategies for building a multi-submission strategy and academia-industry collaborations in the pursuit of […]

THE 4TH GALIEN FORUM EVENT

The 2013 Galien Forum will take place at the Alexandria Center for Life Science on the morning of October 22nd, 2013, and will feature round table debates focusing on critical global healthcare issues and challenges. The annual life science Forum is rapidly becoming a leading event for discussing issues of innovation in the industry. The […]

ASSOBIOTEC – FREEMIND GROUP PRESENTATION: NIH/DOD Non-dilutive Funding Opportunities; non-US applicants are welcome!

Currently, the National Institutes of Health (NIH) are actively funding 1,124 projects amounting to $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above. In this presentation Ayal Ronen, […]